Form D · Biotechnology
Reviticell Holdings, Inc.
Jacksonville, FL · CIK 0001660802
Offering snapshot reported Jan 22, 2016 · SEC filing
- Reported sold
- $1.6M Offering amount: $5.6M
- Investors reported
- 33 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 4, 2011 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 22, 2016 | Amendment | $1,600,383 | $0vs Jan 20, 2016 | 33 | SEC filing |
| Jan 20, 2016 | Initial | $1,600,383 | No comparison | 33 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06c
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-255551
$1,600,383 was sold under the 506(b) exemption. $4,000,000 is being offered under the 506(c) exemption.
Source: Form D, filed Jan 22, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gregory G. Bendis | Director, Executive, Promoter |
| Leslie Frilling | Director, Executive |
| Sue Fritts | Director, Executive |
| Gary Granfield | Director, Executive |
| Christine Granfield | Director |
| John D. Murray, Md | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:Jacksonville, FL, 32256